Abstract
While there have been advances in the field of pulmonary arterial hypertension (PAH), disease management remains suboptimal for many patients. The development of novel treatments and strategies can provide opportunities to target other mechanisms that play a role in the complex pathobiology of PAH outside of the three main pathophysiological pathways. In this review, we highlight some of the potential PAH therapies or techniques that are being, or have been, investigated in phase II clinical trials. This review also discusses potential points for consideration in the development of novel therapies that target putative disease mediators or modifiers.
Abstract
Novel therapies and well-designed trials are important for improving the management of PAH patients http://ow.ly/YHPY304XdvH
Footnotes
Editorial comment in Eur Respir Rev 2016; 25: 361–363.
Conflict of interest: Disclosures can be found alongside this article at err.ersjournals.com
Provenance: The European Respiratory Review received sponsorship from Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, for the publication of these peer-reviewed articles.
- Received August 18, 2016.
- Accepted September 27, 2016.
- Copyright ©ERS 2016.
ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.